8-K: Aptose Biosciences Secures Interest Payment Deferral from Hanmi Amidst Planned $15 Million Capital Raise

Aptose Biosciences Inc. has entered into an agreement with Hanmi Pharmaceutical Co., Ltd. to defer interest payments until December 31, 2025, as it plans to raise $15 million through various offerings.

Summary

• Aptose Biosciences Inc. (Aptose) and Hanmi Pharmaceutical Co., Ltd. (Hanmi) entered into an Interest Deferral Agreement on June 24, 2025.
• This agreement defers the payment of interest from the period commencing December 21, 2024, and ending March 31, 2025 (First Deferred Interest Period), which was originally due by June 27, 2025.
• The agreement also defers interest for the period commencing March 31, 2025, and ending June 30, 2025 (Second Deferred Interest Period).
• Both deferred interest amounts are now due no later than December 31, 2025, or within two business days following the final closing date of a planned capital raise, whichever is earlier.
• Aptose aims to raise $15,000,000 through At-the-Market offerings, Committed Equity Facility, and/or private and/or public offerings, following the filing of a registration statement on Form S-1 or equivalent.
• The deferred amounts will not be considered a default under the original Facility Agreement, nor will they be subject to default interest, provided they are paid by the new due date.
• Previously, on March 18, 2025, Aptose converted $1,513,533.10 of indebtedness owed to Hanmi into 409,063 common shares of the Company.
• The original Facility Agreement, dated August 27, 2024, stipulated that the loan amounts were to be used solely for Tuspetinib-related business operations.
• Aptose and Hanmi have engaged in good faith negotiations regarding a definitive collaboration agreement by June 30, 2025, which could convert the remaining indebtedness and accrued interest into Hanmi's prepayment of future milestone obligations under the collaboration.

Sentiment

Score: 4

Explanation: The deferral of interest payments indicates financial strain and a need for liquidity management, which is a negative signal. However, the proactive plan for a significant capital raise and ongoing collaboration negotiations with Hanmi provide potential pathways to address these challenges, mitigating the overall negative sentiment to a degree.

Positives

• The interest deferral agreement provides Aptose with additional liquidity and flexibility by postponing immediate interest payment obligations.
• The deferral prevents Aptose from being in default under the Facility Agreement and avoids incurring default interest.
• Aptose is actively pursuing a significant capital raise of $15 million, which, if successful, would strengthen its financial position.
• Ongoing good faith negotiations with Hanmi for a potential collaboration agreement could lead to a strategic partnership and debt conversion.

Negatives

• The need for an interest deferral suggests existing liquidity challenges or a desire to conserve cash, indicating financial pressure.
• Reliance on a future capital raise introduces uncertainty, as its success and terms are not guaranteed.
• The collaboration agreement with Hanmi is not yet definitive, and there are no obligations until it is executed, leaving future debt treatment uncertain.

Risks

• Ability to negotiate and execute a definitive collaboration agreement to jointly develop tuspetinib with Hanmi.
• Ability to successfully complete the planned $15 million capital raise through At-the-Market offerings, Committed Equity Facility, and/or private/public offerings.
• Ability to remain compliant with Nasdaq listing requirements.
• General business, economic, competitive, political, and social uncertainties and contingencies that could materially affect actual results.

Future Outlook

Aptose Biosciences is focused on completing a $15 million capital raise to strengthen its financial position and continues to negotiate a definitive collaboration agreement with Hanmi Pharmaceutical, which could lead to the conversion of outstanding debt into prepayment for future milestone obligations related to Tuspetinib.

Management Comments

• Aptose Biosciences Inc. has entered into an Interest Deferral Agreement with Hanmi Pharmaceutical Co., Ltd. to further defer interest payments due under the loan facility agreement.

Industry Context

Aptose Biosciences operates in the clinical-stage precision oncology sector, specifically focusing on developing therapies for acute myeloid leukemia (AML). The deferral of interest payments and the planned capital raise highlight the significant capital requirements and financial management challenges common for clinical-stage biotechnology companies, which often rely on external funding to advance their drug development pipelines.

Comparison to Industry Standards

• The document does not provide specific financial performance metrics (e.g., revenue, profit, EBITDA) that would allow for a direct comparison to industry standards or specific comparable companies/projects. The focus is on financing and debt management rather than operational results.
• The need for interest deferral and a capital raise is not uncommon for clinical-stage biotech companies, which typically operate at a loss and require significant investment to fund R&D and clinical trials, such as those for Tuspetinib in AML.

Related Party Transactions

• The Facility Agreement and subsequent Interest Deferral Agreement are between Aptose Biosciences Inc. and Hanmi Pharmaceutical Co., Ltd., a significant lender and potential strategic partner. This ongoing financial relationship and the debt conversion/deferral arrangements constitute related party dealings.

Stakeholder Impact

• Shareholders: Potential for dilution from the planned $15 million capital raise; financial stability impacts share value.
• Hanmi Pharmaceutical Co., Ltd. (Lender): Agreement to defer payments provides flexibility to Aptose but extends the repayment timeline for Hanmi; potential for future collaboration and debt conversion.
• Employees: Continued operations and drug development efforts are supported by financial stability and capital raises.
• Customers/Patients (future): Continued development of Tuspetinib for AML is dependent on sustained funding and successful clinical trials.

Next Steps

• Complete the planned $15 million capital raise.
• Continue negotiations with Hanmi Pharmaceutical Co., Ltd. to finalize a definitive collaboration agreement.
• Make the deferred interest payments by December 31, 2025, or earlier, following the capital raise.

Key Dates

Recommendation

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Interest Deferral Agreement, Capital Raise, SEC Filing, 8-K, Tuspetinib, AML, Oncology, Biotechnology, Loan Facility, Debt Management, Corporate Finance